journal cover

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies

JAMA Oncology

Jul 17, 2015

Jeffrey S RossPhilip J Stephens

Download from

Publisher
PubMed

Abstract

For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome. To discover opportunities for targeted therapies in patients with CUP not currently searched for in routine practice. Comprehensive genomic profiling ...read more

Mentioned in this Paper

TP53 gene
MAP2K1 protein, human
HRAS
BRCA2 Protein
ErbB-2 Receptor
Genetic Analysis RET Proto-oncogene Assay
EGFR
SMAD4
FGFR1
NRAS gene
101
9
9
94
Paper Details
References
  • References54
  • Citations27
12345...
  • References54
  • Citations27
123

Feeds With Similar Papers

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Precision Medicine

Precision medicine is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to the patient traits and specific molecular features of disease processes. In this model, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis. Tools employed in precision medicine can include molecular diagnostics, imaging, and analytics

Hereditary Cancer Syndromes

Hereditary cancer syndromes comprise 5% of all cancers and have an increased risk of early onset and of multiple or bilateral malignancies. Here is the latest research on hereditary cancer syndromes.

MAPK Pathway

MAPK pathway is a complex signaling pathway that regulates transcription, translation, cell cycle, and proliferation. Targeting this pathway has long been considered a promising strategy for cancer therapy. Here is the latest research on this pathway.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Neurofibromatosis 1

Neurofibromatosis 1 (NF1), also known as von Recklinghausen disease, is an autosomal dominant condition caused by mutations in the NF1 gene. Here is the latest research.

Type 2 Neurofibromatosis

Type 2 Neurofibromatosis are rare inherited autosomal dominant diseases caused by the NF2 gene. It is characterized by the growth of noncancerous tumors in the nervous system, specifically along the auditory nerve. Symptoms include hearing loss, tinnitus, and balance problems. Here is the latest research on Type 2 Neurofibromatosis.

SWI/SNF Complex in Cancer (Keystone)

Mutations in the ATP-dependent chromatin remodelling SWI/SNF complexes have been found in cancer and implicate SWI/SNF complexes as potential tumor suppressors. Discover the latest research on the SWI/SNF complex in cancer here.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

PTEN Tumour Suppressor

PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor is a PI (phosphoinositide) 3-phosphatase that can inhibit cellular proliferation, survival and growth by inactivating PI 3-kinase-dependent signalling. It also suppresses cellular motility through mechanisms that may be partially independent of phosphatase activity. PTEN is one of the most commonly lost tumour suppressors in human cancer, and its deregulation is also implicated in several other diseases.

Personalized cancer medicine

Personalized cancer medicine include studying a person's genetic makeup and tumor growth to prevent, diagnose and/or treat disease. Here is the latest research on personalized cancer medicine.

Next-Generation Therapeutics

Gene therapy and protein engineering strategies, guided by biological principles, are allowing ligands and receptors to be developed as next-generation therapeutics with improved safety and efficacy. Discover the latest research here.

Precision Oncology

Precision oncology is a new approach to cancer treatment, which utilizes the molecular profiling of each tumor to develop and tailor treatment strategies to each patient. The use of these biomarkers from tumors will help to predict those who will respond to specific treatments. Here is the latest research on precision oncology.

G-Protein-Coupled Receptors

G-protein-coupled receptors (GPCRs), the largest family of integral membrane proteins, participate in the regulation of many physiological functions and are the targets of approximately 30% of currently marketed drugs. Here is the latest research.

Consumer Genomics

Consumer genomics is a rapidly advancing industry with the ability to gather large databases of genetic information of individual data. This information will allow people the ability to adapt their lifestyle and potentially modify disease trajectories in the future. Discover the latest research on consumer genomics here.

Enhancer Decommissioning (Keystone)

Enhancers are regions of DNA that can be bound by proteins to increase the likelihood of transcription. Follow this feed to discover research relate to enhancer decommissioning.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Neurofibromatosis

Neurofibromatosis is a genetic disorder that causes tumors to form in the central nervous system. While these tumors are typically benign, they can become malignant. Other complications of neurofibromatosis include hearing loss, learning impairment, vision loss, etc. Here is the latest research.

SMARCA4 Mutations In Cancer (Keystone)

SMARCA4 is an ATP-dependent chromatin remodeler which is a member of the SWI/SNF protein family and works to activate or repress transcription. Mutations in SMARCA4 have been associated with cancer. Follow this feed for the latest research on SMARC4A mutations and carcinogenesis.

Targeting ALK: Precision Medicine

Anaplastic Lymphoma Kinase (ALK) is an oncogene frequently found as a fusions in non-small cell lung cancer (NSCLC), as EML4-ALK. Precision medicine uses therapeutic agents that target specific mutations, such as those found in ALK-positive NSCLC patients. Discover the latest research on Targeting ALK here.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

© 2020 Meta ULC. All rights reserved

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies

JAMA Oncology

Jul 17, 2015

Jeffrey S RossPhilip J Stephens

PMID: 26182302

DOI: 10.1001/jamaoncol.2014.216

Abstract

For carcinoma of unknown primary site (CUP), determining the primary tumor site may be uninformative and often does not improve outcome. To discover opportunities for targeted therapies in patients with CUP not currently searched for in routine practice. Comprehensive genomic profiling ...read more

Mentioned in this Paper

TP53 gene
MAP2K1 protein, human
HRAS
BRCA2 Protein
ErbB-2 Receptor
Genetic Analysis RET Proto-oncogene Assay
EGFR
SMAD4
FGFR1
NRAS gene
101
9
9
94

Feeds With Similar Papers

Cancer Genomics

Cancer genomics employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research here.

Precision Medicine

Precision medicine is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to the patient traits and specific molecular features of disease processes. In this model, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis. Tools employed in precision medicine can include molecular diagnostics, imaging, and analytics

Related Papers

Paper Details
References
  • References54
  • Citations27
12345...
  • References54
  • Citations27
123

Download from

Publisher
PubMed
/papers/comprehensive-genomic-profiling-of-carcinoma-of/26182302